TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15855978

Group type: EXPERIMENTAL
Intervention: Wireless capsule endoscopy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Barium contrast series
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 24
Study: 12477214

Group type: EXPERIMENTAL
Intervention: Usual treatment plus a patient education program (Group B)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Usual treatment (Group A)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Usual treatment plus a patient education program (Group B) in moderate-to-severe asthma
Number of subjects: 77
Study: 9658727

Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (1.5 g/m2 i.v. day 0) plus G-CSF (5 ug/kg/day s.c. from day +1 to end of leukapheresis)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide plus G-CSF
Number of subjects: 28
Study: 8294680

Group type: COMPARATOR
Intervention: Biphasic defibrillation alone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sequential defibrillation alone
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combined biphasic plus sequential defibrillation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combined waveform
Number of subjects: 13
Study: 2962947

Group type: EXPERIMENTAL
Intervention: Yeast-derived hepatitis B vaccines (partially purified or highly purified)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Plasma-derived hepatitis B vaccine (control)
Number of subjects: 50
Study: 31935168

Group type: EXPERIMENTAL
Intervention: Bioceramic (BC) group wearing compressive socks made of fabrics with embedded ceramic powder for 8 hours a day for 28 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo group wearing compressive socks of the same material without ceramic powder
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bioceramic (BC) group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 30
Study: 30089607

Group type: EXPERIMENTAL
Intervention: Therapist-assisted Internet-Based Cognitive Behavioral Therapy (iCBT)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Therapist-assisted Internet-Based Standard Progressive Relaxation Training (iPRT)
Number of subjects: 179
Study: 28162905

Group type: EXPERIMENTAL
Intervention: Bilateral arm training (30 minutes, additional to general occupational therapy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: General occupational therapy (30 minutes)
Number of subjects: 30
Study: 26591678

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Diclofenac sodium (medication group)
Number of subjects: 120
Study: 23413266

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 126
Study: 21540753

Group type: EXPERIMENTAL
Intervention: Combined exercise training (EX) - concurrent circuit resistance exercise (RE) followed by endurance exercise (EE) at 60% of predicted maximal heart rate, 3 days per week
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined exercise training (EX)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No exercise control
Number of subjects: 24
Study: 18344729

Group type: EXPERIMENTAL
Intervention: Venlafaxine 300 mg/d
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 16858462

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Social Problem-Solving Inventory‐Revised
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Profile of Mood States
Number of subjects: 66
Study: 14533211

Group type: EXPERIMENTAL
Intervention: 24 hourly change of closed suction catheter (CSC)
Number of subjects: 158

Group type: COMPARATOR
Intervention: 48 hourly change of closed suction catheter (CSC)
Number of subjects: 158
Study: 10761291

Group type: EXPERIMENTAL
Intervention: Primary and secondary PPV without autologous thrombocyte concentrate (ATC)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Primary and secondary PPV with early increase of IOP
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sub-group B1 (maximum postoperative IOP deviation between 25-35 mm Hg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sub-group B2 (maximum postoperative IOP deviation above 35 mm Hg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Administration of ATC during PPV
Number of subjects: 75
Study: 8973986

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study: 1606213

Group type: EXPERIMENTAL
Intervention: 1 hour educational package + 1 hour group discussion intervention (75% of subjects)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Presence of a person with AIDS (PWA) during group discussion (in person or on video)
Number of subjects: 118
Study: 3709614

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg (single and multiple doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg (single dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both drugs (single and multiple doses)
Number of subjects: 12
Study: 30878630

Group type: EXPERIMENTAL
Intervention: High dose tigecycline (100 mg q12h)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard dose tigecycline (50 mg q12h)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cured group
Number of subjects: 105

Group type: COMPARATOR
Intervention: Failure group
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: AUIC
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: MIC
Number of subjects: 105
Study: 29481447

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy with 30 J
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy with 15 J
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy with 60 J
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 27134061

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (tryptophan, tyrosine, phenylalanine)
Number of subjects: 111
Study: 24708507

Group type: EXPERIMENTAL
Intervention: Crying sound during separation phase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laughing sound during separation phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crying sound during response phase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laughing sound during response phase
Number of subjects: 0
Study: 22178762

Group type: EXPERIMENTAL
Intervention: Standard therapy plus a psychoeducational group intervention on alcohol drinking related to stress and trauma (PAST)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 66
Study: 20647198

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m²/week for 4 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide for 3 to 6 months followed by azathioprine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide
Number of subjects: 44
Study: 18572030

Group type: EXPERIMENTAL
Intervention: Cypher Select stent (n = 48)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Taxus Express-2 stent (n = 47)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Cypher Select stent (n = 40)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Taxus Express-2 stent (n = 38)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Stent type
Number of subjects: 95
Study: 15765953

Group type: EXPERIMENTAL
Intervention: Super‐Torque Lux 3 650B (KaVo, Biberach, Germany)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BORA 898LE (BienAir SA, Bienne, Switzerland)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Toplight (W&H Dentalwerk, Burmoos, Austria)
Number of subjects: 20
Study: 12061197

Group type: EXPERIMENTAL
Intervention: Icodextrin-based dialysis solution
Number of subjects: 18

Group type: COMPARATOR
Intervention: Glucose-based dialysis solution
Number of subjects: 18
Study: 10363074

Group type: EXPERIMENTAL
Intervention: ketorolac 10 mg p.o. (t.i.d.)
Number of subjects: 138

Group type: COMPARATOR
Intervention: diclofenac 50 mg p.o. (t.i.d.)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: ketorolac
Number of subjects: 138

Group type: COMPARATOR
Intervention: diclofenac
Number of subjects: 138
Study: 8650509

Group type: EXPERIMENTAL
Intervention: Individually based physiotherapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Group exercise
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 33
Study: 2202655

Group type: EXPERIMENTAL
Intervention: 0.5% idoxuridine cream
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.25% idoxuridine cream
Number of subjects: 50
Study: 7428566

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 26

Group type: COMPARATOR
Intervention: Aldomet
Number of subjects: 26
Study: 31925601

Group type: EXPERIMENTAL
Intervention: adapted parent‐child interaction therapy intervention with foster‐parent child dyads
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: multiple evidence-based treatments (EBTs)
Number of subjects: 0
Study: 29955828

Group type: EXPERIMENTAL
Intervention: Varenicline adherence (≥80%)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Varenicline adherence (not adherent)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Early reductions in depressed mood and satisfaction from smoking
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Greater adherence
Number of subjects: 207
Study: 28086857

Group type: EXPERIMENTAL
Intervention: Social behaviour change communication (SBCC) strategy involving a radio drama and community mobilization
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Radio programming alone
Number of subjects: 1440
Study: 25909422

Group type: EXPERIMENTAL
Intervention: Mepilex Ag dressing applied every 5 to 7 days (n = 71)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Silver sulfadiazine (SSD) applied daily (n = 82)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Silver sulfadiazine (SSD)
Number of subjects: 153
Study: 23371005

Group type: EXPERIMENTAL
Intervention: Provictim attitudes (defined as children's beliefs that bullying is unacceptable, victims are acceptable, and defending victims is valued)
Number of subjects: 16634

Group type: EXPERIMENTAL
Intervention: Teachers' ability to intervene in bullying (assessed at the classroom level)
Number of subjects: 16634
Study: 21288733

Group type: EXPERIMENTAL
Intervention: CoSeal® surgical sealant
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 121
Study: 19053983

Group type: EXPERIMENTAL
Intervention: PEG/RBV
Number of subjects: 232
Study: 17234675

Group type: EXPERIMENTAL
Intervention: EMLA cream (lidocaine 25 mg-prilocaine 25 mg/G) applied to the uterine cervix 30 min before HSG
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo cream applied to the uterine cervix 30 min before HSG
Number of subjects: 82
Study: 15612846

Group type: EXPERIMENTAL
Intervention: High improved symptom trajectory
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: High unimproved symptom trajectory
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Borderline improved symptom trajectory
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Borderline unimproved symptom trajectory
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Subclinical symptom trajectory
Number of subjects: 156
Study: 11352442

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Moxifloxacin 400mg with Al3+ (sucralfate) 190mg
Number of subjects: 12
Study: 9404449

Group type: EXPERIMENTAL
Intervention: Hexarelin 0.25 microgram/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hexarelin 0.5 microgram/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hexarelin 2.0 micrograms/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GHRH 1.0 microgram/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pyridostigmine 120 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pyridostigmine + Hexarelin 0.25 microgram/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pyridostigmine + GHRH
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hexarelin 0.25 microgram/kg + GHRH
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pyridostigmine + Hexarelin 0.5 microgram/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pyridostigmine + Hexarelin 2.0 micrograms/kg
Number of subjects: 6
Study: 7855193

Group type: EXPERIMENTAL
Intervention: Alcohol group A (0.62 g/kg) with withholding knowledge of results (KR)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alcohol group AM (0.62 g/kg) with incentive for nonimpaired performance
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Group PM (incentive without KR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Group PC (continued KR)
Number of subjects: 24
Study: 3607147

Group type: EXPERIMENTAL
Intervention: 25 grams of glucose
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28875242

Group type: EXPERIMENTAL
Intervention: Needs-based education
Number of subjects: 450

Group type: COMPARATOR
Intervention: Traditional education
Number of subjects: 450
Study: 27965882

Group type: EXPERIMENTAL
Intervention: Optimal Personalised Care After Treatment for Gynaecological cancer (OPCAT-G) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 25211663

Group type: EXPERIMENTAL
Intervention: HER2/neu positive cases
Number of subjects: 1645

Group type: EXPERIMENTAL
Intervention: HER2/neu positivity
Number of subjects: 1645

Group type: EXPERIMENTAL
Intervention: HER2/neu positive status in sigmoideal and rectal carcinomas
Number of subjects: 1645

Group type: EXPERIMENTAL
Intervention: HER2/neu positive colorectal carcinomas
Number of subjects: 1645
Study: 21807750

Group type: EXPERIMENTAL
Intervention: 4 weeks of guided self-help intervention targeting abstract rumination
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waiting-list control condition receiving treatment as usual
Number of subjects: 34
Study: 20588170

Group type: EXPERIMENTAL
Intervention: Latest CD4(+) cell count
Number of subjects: 3012

Group type: EXPERIMENTAL
Intervention: CD4(+) slope < -10 cells/microl per month
Number of subjects: 3012

Group type: COMPARATOR
Intervention: Non-AIDS deaths
Number of subjects: 3012

Group type: COMPARATOR
Intervention: Non-AIDS events
Number of subjects: 3012
Study: 19001323

Group type: EXPERIMENTAL
Intervention: Consolidation docetaxel 75 mg/m2 IV every 21 days for three cycles
Number of subjects: 203

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Overall survival comparison
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Toxicities during docetaxel
Number of subjects: 203
Study: 16430387

Group type: EXPERIMENTAL
Intervention: Telemonitoring using the @HOME platform
Number of subjects: 108

Group type: COMPARATOR
Intervention: Self-report
Number of subjects: 108

Group type: COMPARATOR
Intervention: Pill counting
Number of subjects: 108
Study: 12791563

Group type: EXPERIMENTAL
Intervention: Early attachment-oriented preventive psychotherapeutic intervention program
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 87
Study: 10321786

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 51
Study: 7493593

Group type: EXPERIMENTAL
Intervention: Semantic priming task for older adults
Number of subjects: 0

Group type: COMPARATOR
Intervention: Semantic priming task for young adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inconsistent responding older individuals
Number of subjects: 0
Study: 1673478

Group type: EXPERIMENTAL
Intervention: Nicardipine (30 mcg.kg‐1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Verapamil (50 mcg.kg‐1)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no Ca entry blocker)
Number of subjects: 21
Study: 6956947

Group type: EXPERIMENTAL
Intervention: Indomethacin (enteral route)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 26
Study: 31701799

Group type: EXPERIMENTAL
Intervention: rosiglitazone with spironolactone (R + S)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: rosiglitazone with metformin (R + M)
Number of subjects: 138

Group type: COMPARATOR
Intervention: rosiglitazone (R)
Number of subjects: 138
Study: 31073102

Group type: EXPERIMENTAL
Intervention: NC120
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 27994065

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy
Number of subjects: 85
Study: 25744509

Group type: EXPERIMENTAL
Intervention: High amylose maize resistant starch (RS) incorporated into fried wheat flour dough, given twice daily for 28 days.
Number of subjects: 17
Study: 24885993

Group type: EXPERIMENTAL
Intervention: 0.03% transfluthrin coils alone
Number of subjects: 7341

Group type: EXPERIMENTAL
Intervention: Deltamethrin long-lasting insecticide treated nets (LLINs) alone
Number of subjects: 7341

Group type: EXPERIMENTAL
Intervention: Combination of transfluthrin coils and deltamethrin LLINs
Number of subjects: 7341

Group type: COMPARATOR
Intervention: Control arm (nothing)
Number of subjects: 7341
Study: 22859243

Group type: EXPERIMENTAL
Intervention: NB-001 (0.3%)
Number of subjects: 482
Study: 19629023

Group type: COMPARATOR
Intervention: Paroxetine (PAROX)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitors (MAOIs)
Number of subjects: 52
Study: 17317358

Group type: EXPERIMENTAL
Intervention: TAXUS stent
Number of subjects: 155

Group type: COMPARATOR
Intervention: bare metal stent
Number of subjects: 155
Study: 15169848

Group type: EXPERIMENTAL
Intervention: Combination of ascorbic acid (500 mg day(‐1)) and RRR‐alpha‐tocopherol (400 i.u. day(‐1))
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 11489683

Group type: EXPERIMENTAL
Intervention: Bicalutamide (150 mg daily)
Number of subjects: 3603

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3603
Study: 9564984

Group type: EXPERIMENTAL
Intervention: Terfenadine with erythromycin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Terfenadine without erythromycin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Astemizole without erythromycin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Loratadine without erythromycin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cetirizine without erythromycin
Number of subjects: 80
Study: 7981579

Group type: EXPERIMENTAL
Intervention: Nicotine 0.014 mg/kg body weight
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nicotine 0.028 mg/kg body weight
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (0 mg/kg body weight)
Number of subjects: 48
Study: 3236585

Group type: EXPERIMENTAL
Intervention: Cued recall test
Number of subjects: 54

Group type: COMPARATOR
Intervention: Recognition test
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Successive testing (recognition followed by recall)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Reverse order testing (recall followed by recognition)
Number of subjects: 54
Study: 4666629

Group type: EXPERIMENTAL
Intervention: Intra-amniotic prostaglandin F2α and intravenous oxytocin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Intra-amniotic prostaglandin F2α alone
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Intra-amniotic prostaglandin F2α with oxytocin
Number of subjects: 57
Study: 29428199

Group type: EXPERIMENTAL
Intervention: sST2 concentration in AF patients
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: sST2 concentration in emergency AF patients
Number of subjects: 254

Group type: COMPARATOR
Intervention: sST2 concentration in AF outpatients
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: sST2 concentration in paroxysmal AF patients
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: sST2 concentration in persistent AF patients
Number of subjects: 254

Group type: COMPARATOR
Intervention: sST2 concentration in healthy individuals
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: sST2 concentration as a predictor
Number of subjects: 254
Study: 27429113

Group type: EXPERIMENTAL
Intervention: Combined alfacalcidiol and metformin therapy (Group 2)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Metformin (Group 3)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Alfacalcidiol (Group 1)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 39
Study: 24939928

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3202

Group type: COMPARATOR
Intervention: Heparin plus glycoprotein IIb/IIIa inhibitor
Number of subjects: 3202

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 3202

Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 3202

Group type: EXPERIMENTAL
Intervention: Reinfarction
Number of subjects: 3202
Study: 22835552

Group type: EXPERIMENTAL
Intervention: Pulsatile flow during CPB
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonpulsatile flow during CPB
Number of subjects: 20
Study: 20420643

Group type: EXPERIMENTAL
Intervention: Once daily calcineurin inhibitor (CNI) monotherapy at half their previous dose
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Once daily calcineurin inhibitor (CNI) monotherapy
Number of subjects: 56
Study: 18684276

Group type: EXPERIMENTAL
Intervention: Acoustic cardiography (EMAT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Doppler echocardiography (transmitral flow assessment)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Doppler echocardiography (VTI)
Number of subjects: 43
Study: 16882425

Group type: EXPERIMENTAL
Intervention: Lap Loop device
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional methods (laparoscopic monopolar scissors or Harmonic scalpel)
Number of subjects: 29